During the past decade, CHU Tivoli conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 9 clinical trials were completed, i.e. on average, 39.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Tivoli" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Henogen" with 4 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored and "Bayer" with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Tivoli" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "GlaxoSmithKline" with 3 trials as a collaborator, "Belgium Health Care Knowledge Centre" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator and "Central European Myeloma Study Group" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "CHU Tivoli" are "Hepatitis B" (4 trials), "Breast Cancer" (2 trials), "Heart Failure" (2 trials), "Multiple Myeloma" (2 trials) and "Multiple Sclerosis" (2 trials). Many other conditions were trialed in "CHU Tivoli" in a lesser frequency.

Most popular intervention types in "CHU Tivoli" are "Drug" (27 trials), "Biological" (6 trials), "Other" (5 trials), "Device" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (6 trials), "Placebo" (6 trials), "Empagliflozin" (4 trials), "HBVAXPRO vaccine" (2 trials) and "radiation therapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU Tivoli" are 35 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Tivoli". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in CHU Tivoli, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Tivoli, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".